Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $13.36, but opened at $12.37. Ginkgo Bioworks shares last traded at $12.08, with a volume of 301,887 shares trading hands.
Ginkgo Bioworks Stock Down 5.7 %
The stock’s 50-day moving average is $10.35. The firm has a market cap of $724.54 million, a price-to-earnings ratio of -0.97 and a beta of 1.16.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of DNA. KBC Group NV bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth approximately $31,000. Palumbo Wealth Management LLC bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth approximately $144,000. SG Americas Securities LLC bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth approximately $199,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Ginkgo Bioworks by 644.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock worth $263,000 after purchasing an additional 27,978 shares during the last quarter. Finally, FNY Investment Advisers LLC grew its holdings in shares of Ginkgo Bioworks by 125.6% in the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock worth $745,000 after purchasing an additional 42,298 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- What Are Dividend Champions? How to Invest in the Champions
- Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
- Best Aerospace Stocks Investing
- Big Dividend Hikes: 4 Large-Cap Stocks Increasing Payouts
- 3 Fintech Stocks With Good 2021 Prospects
- Procter & Gamble: A Consumer Staples Titan Built to Win
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.